novel dihydrofolate reductase inhibitors. structure- based versus diversity-based design and high-...

18
Novel Dihydrofolate Reductase Inhibitors. Structure-Based versus Diversity-Based Design and High-Throughput Synthesis and Screening Pierre C. Wyss, Paul Gerber, Peter G. Hartman, Christian Hubschwerlen, Hans Locher, Hans-Peter Marty, Martin Stahl F. Hoffman-La Roche Ltd, Basel Switzerland J. Med. Chem. 2003, 46, 2304 Kiran-20060214

Post on 19-Dec-2015

222 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Novel Dihydrofolate Reductase Inhibitors. Structure-Based versus Diversity-Based Design and High-

Throughput Synthesis and Screening

Pierre C. Wyss, Paul Gerber, Peter G. Hartman, Christian Hubschwerlen, Hans Locher, Hans-Peter Marty, Martin Stahl

F. Hoffman-La Roche Ltd, Basel Switzerland

J. Med. Chem. 2003, 46, 2304

Kiran-20060214

Page 2: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

• The spread of antibiotic resistance has led to a renewed / ongoing search for new targets and new antibacterial compounds

• DHFR plays a key role in the synthesis of amino acids and purines. DHFR null bacteria are not viable

• Bacteria are gram +ve or gram –ve depending on whether they stain purple or pink with the Gram stain

• Boils, pimples, strep throat, ear infections, nosocomial infections, pneumonia etc. are caused bacteria

• Trimethoprim (TMP) was already in clinical use at the time this work was done

• Hoffmann-La Roche had RO-64-5781 in hand, it was 190,000 times more potent than TMP but it was not druggable.

• IC50: concentration required to suppress 50% of bacterial growth• MIC: lowest concentration that will inhibit bacterial growth 100% after

overnight incubation (IC100)

Biology

Page 3: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Goal and methods

• Design novel DHFR inhibitors with good drug-like properties

• Two methods evaluated:

- Structure-based library design

• Crystal structures for DHFR known

• Potent compounds known

- Diversity-based library design

• Known potent compounds had high molecular weights, were highly plasma protein bound and showed poor solubility

• Design compounds of a different structural class and reduced molecular weight

• Selectivity

- Inhibit bacterial DHFRs but not human DHFR

Page 4: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Basic idea for library design

• Replace the greasy hydrophobic piece (red), keep the diaminopyrimidine piece (blue)

Page 5: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Testing synthetic feasibility

- Compound 6 is good practical chemistry, is a key intermediate for library synthesis

- Reactions could be done on 0.35 - 0.7 M scale

- Purification by HPLC not required

- 1392 compounds made in library format

Page 6: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Paradigm for structure-based virtual screening

- Diaminopyrimidine is an ideal fit for a narrow pocket in the active site: “needle”

- Docking would be done with the constraint of a fixed position for the needle fragment

N

N

complexed with S. aureus DHFR

Page 7: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Homology model for structure-based screening

• Sa: TMP-sensitive S. aureus DHFR• Hum: human DHFR• Spn: TMP-sensitive S. pneumoniae DHFR• Sp1: TMP-resistant S. pneumoniae DHFR

- No significant induced fit effects can be observed, assume receptor is rigid for docking experiments- High similarity at the active site, assume that use of a single crystal structure will be sufficient for screening against all targets

Page 8: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Structure-based compound selection: method

• 9948 secondary amines retrieved as virtual reagents

• Single 3D conformations were generated using Corina

• The protonation states were adjusted, the nitrogen on

the aminomethyl substituent was not protonated

• The single crystal structure of DHFR from TMP-sensitive S. aureus complexed with RO-62-6091 was used

• Library members were docked with a fixed position (taken from the crystal structure) for the 2,4-diaminopyrimidine piece

• FlexX was used for docking experiments, hydrogen bonds formed at solvent-exposed regions of the enzyme were penalized.

Page 9: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Structure-based compound selection: results

• FlexX produced docking results for about half of the library

• For each compound the solution with the highest binding energy was selected

• 252 of the 300 top-ranked candidates were synthesized (LIBRARY 1)

• 150 candidates were selected randomly from compounds for which no docking solution could be found.

• Another 150 lowest-ranked compounds were selected

• 269 of these 300 compounds were synthesized (LIBRARY 2)

Page 10: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Some observations from FlexX docking

• Hits from LIBRARY 1 were more active against Spn DHFR even though the crystal structure of Sa DHFR had been used i.e. “the power of virtual screening lies in its ability to filer out undesirable compounds rather than identifying specific active ones”

– FlexX does not find docking solutions for compounds with more than one bulky substituent at the aminomethyl nitrogen.

– FlexX discards very small molecules and compounds with long flexible moieties.

– FlexX assigns high ranks to conformationally restricted flat rigid polycyclic motifs: an additional 370 compounds (LIBRARY 4)

Page 11: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

• The library of 9448 virtual reagents was clustered according to chemical similarity- Compounds were superimposed in pairs at the newly

formed C-N bond- The amine substituent was rotated. Conformers with maximum volume and H-bond-donor and H-bond-acceptor overlap were generated.- The list of pairwise similarity scores was used for clustering in a binary tree using a complete linkage algorithm

-- two clusters are combined only if all members of the first are within the distance threshhold of all members of the second

-- Each iteration reduces the number of clusters by one

Results:

• About 500 compounds were needed to adequately represent the chemical space of the library, a set of 501 compounds was synthesized (LIBRARY 3)

Diversity-based compound selection: method & results

Page 12: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Experimental validation and results

• Primary high throughput screen against Sa DHFR and Spn DHFR at 10 M, select compounds that show >50% inhibition

• Screen at 25 M for antibacterial activity

• Also test for thymidine antagonism and activity in the presence of 10% human serum

Page 13: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

IC50s (M) against Spn DHFR for hits from Library 1

0.075

1.10.01

0.0440.007

0.012

0.0210.0098

0.006

0.045

0.002

0.004

0.004

Page 14: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Selectivity for hits from Library 1

- Except for compound 11, all the compounds were more active against Spn/Sp1- Only 10 and 13 showed selectivity for bacterial DHFR over Human DHFR compared to TMP- The R isomer of 9 helped identify a new cleft in the enzyme

Page 15: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Crystal Structure of (R)-9

N

N

Page 16: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Summary

• Overall, the structure-based method gave better results

• Potent and selective inhibitors of wild type and TMP-resistant S. pneumoniae DHFR were identified

• The new class of inhibitors had features for better physicochemical properties

Page 17: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Discussion

• The same set of 9948 amines was used for both libraries. But the diversity library gave a poor hit rate. Can that be improved?

• Is there enough information now available to attempt virtual prediction of selectivity (human vs bacterial DHFR?)

Page 18: Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul

Back up